Novavax to Participate in Fireside Chat at Devex @ UNGA 76
PR91797
GAITHERSBURG, Md., Sept. 21, 2021 /PRNewswire=KYODO JBN/ --
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and
commercializing next-generation vaccines for serious infectious diseases, today
announced that John J. Trizzino, Executive Vice President, Chief Commercial
Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on
September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is
taking place September 21-23 via livestream as part of its coverage of the 76th
meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19
vaccine candidate, NVX-CoV2373, will be a topic of discussion along with
fostering global vaccine access.
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
Interview details are as follows:
Date: Tuesday, September 21, 2021
Time: 8:50 - 9:05 a.m.
Location: Livestream ( https://pages.devex.com/devex-at-unga-76.html )
Title: Fireside chat: A status report on the COVID-19 vaccine rollout
Novavax panelist: John J. Trizzino, Executive Vice President, Chief Commercial
Officer and Chief Business Officer
Moderator: Jenny Lei Ravelo, Senior Reporter, Devex
For more information or to register for the fireside chat, visit:
https://pages.devex.com/devex-at-unga-76.html
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved
health globally through the discovery, development and commercialization of
innovative vaccines to prevent serious infectious diseases. The company's
proprietary recombinant technology platform combines the power and speed of
genetic engineering to efficiently produce highly immunogenic nanoparticles
designed to address urgent global health needs. Novavax is conducting
late-stage clinical trials for NVX-CoV2373, its vaccine candidate against
SARS-CoV-2, the virus that causes COVID-19. NanoFlu(TM), its quadrivalent
influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase
3 clinical trial in older adults and will be advanced for regulatory
submission. Both vaccine candidates incorporate Novavax' proprietary
saponin-based Matrix-M(TM) adjuvant to enhance the immune response and
stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter (
) and LinkedIn (
).
Contacts:
Investors
Novavax, Inc.
Erika Schultz | +1 240-268-2022
ir@novavax.com
Solebury Trout
Alexandra Roy | +1 617-221-9197
aroy@soleburytrout.com
Media
Alison Chartan | +1 240-720-7804
Laura Keenan | +1 202-709-7521
media@novavax.com
SOURCE: Novavax, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。